biotechnology

SSTI has released a new data tool that defines investment activity, one indicator of the vibrancy of a region’s innovation economy, in each of 18 technology areas. Comprising two interactive visuals and a downloadable data file, this tool includes the number of investment-backed companies, investment deals, and amount of capital invested by state, year (2013-June 2023), and investment stage (e.g., seed, angel, venture) for technology verticals that were selected to align with many of the key technology areas defined in the CHIPS and Science Act and included in the U.S. Economic Development Administration (EDA) Tech Hubs program.

The White House has released a new report, Building the bioworkforce of the future: Expanding equitable pathways into biotechnology and biomanufacturing jobs. The five core recommendations in the report are intended to help propel continued investment in the bioeconomy and maintain the U.S.’ leadership in this sector. The report follows an Executive Order President Biden signed in September 2022.

The National Science Foundation (NSF) is expanding a network of research centers across the country to translate university-based R&D into new, and hopefully, better advanced materials. In late June, NSF announced the distribution of $162 million to support the creation of nine more Materials Research Science & Engineering Centers (MRSECs), bringing the total number of centers to twenty. Each of the new centers will receive $18 million over six years.

A new report compiled by The White House Office of Science and Technology Policy (OSTP) outlines a whole-of-government approach to biotechnology and making it a national priority. The report lays out bold goals over two decades for biotech R&D, calling for an increase in agricultural productivity by 28% in the next decade and reducing food waste and loss by 50% by 2030.

With the Dec. 20 release of two Requests for Information (RFIs), the White House Office of Science and Technology Policy seeks public input to help guide the development and deployment of the National Biotechnology and Biomanufacturing Initiative, which is intended to use the two disciplines to advance innovative solutions in health, climate change, energy, food security, agriculture, and supply chain resilience.

On the 60th anniversary of President Kennedy's Moonshot Address, President Biden traveled to the John F. Kennedy Presidential Library and Museum to highlight progress toward his administration's Moonshot Program to combat cancer and expand the U.S. bioeconomy. This announcement included Biden's pick for the inaugural director of the Advanced Research Projects Agency for Health (ARPA-H) and the signing of an executive order to institute a National Biotechnology and Biomanufacturing Initiative.

The news that a drug has been developed that appears to significantly reduce the risk of hospitalization or death from COVID-19, understandably garnered international attention. While most of the coverage centered on Merck, dig a bit deeper and one learns that Emory University researchers developed molnupiravir which Merck and Ridgeback Biotherapeutics have licensed. For the TBED community, there is another interesting angle to the story if one goes even further: this work was a result of a non-profit that Emory had set up, Drug Innovation Ventures at Emory (DRIVE), to help bridge the gap between scientific discovery to helping patients.

The U.S. Department of Defense (DoD), through the Office of the Under Secretary of Defense for Research and Engineering (OUSD(R&E)), announced awards totaling $15 million for Historically Black Colleges and Universities (HBCUs) to establish Centers of Excellence (COEs) in Biotechnology and Materials Science. The COEs will provide training to underrepresented students pursuing science, technology, engineering, and mathematics (STEM) disciplines, and will also provide internships at defense laboratories while also offering training to K-12 students to strengthen the talent pool entering the STEM pipeline.

The biotechnology industry has made progress in increasing representation, especially in pre-revenue, smaller and private companies, however, diversity and inclusion programming is still in the nascent stages at most companies responding to a survey by the Biotechnology Innovation Organization (BIO). BIO published its first annual survey on the industry’s progress in its report, Measuring Diversity in the Biotech Industry: Building an Inclusive Workforce.